- Pharmaceutical companies
- Asia
- China
- CSPC Pharmaceutical Group
CSPC Pharmaceutical Group in China
Address:
-
CSPC Pharmaceutical Group Limited
No.226 Huanghe Street, Shijiazhuang, Hebei Province, PRC 050035
Phone: +86(86) 311-8703 7015
Fax: (86) 311-8703 9608
Other CSPC Pharmaceutical Group's locations around the world
Clinical Trials sponsored by CSPC Pharmaceutical Group
-
Wuhan Union Hospital, ChinaCSPC Pharmaceutical Group LimitedRecrutementLeucémie aiguë lymphoblastique à cellules B | Lymphome à cellules B réfractaireChine
-
Tianjin Medical University Second HospitalCSPC Pharmaceutical Group LimitedInconnueCancer de la vessie invasif musculaireChine
-
Second Affiliated Hospital of Guangxi Medical UniversityCSPC Pharmaceutical Group LimitedPas encore de recrutement
-
Peking Union Medical College HospitalCSPC Ouyi Pharmaceutical Group Co., Ltd.Pas encore de recrutementMéningite cryptococciqueChine
-
Sun Yat-sen UniversityInnovent Biologics (Suzhou) Co. Ltd.; CSPC Pharmaceutical Group LimitedComplétéCarcinome épidermoïde de l'œsophageChine
-
Huijing WuBeijing Xisike Clinical Oncology Research Foundation; CSPC Pharmaceutical...RecrutementLymphome T angio-immunoblastiqueChine
-
The First Affiliated Hospital of Xiamen UniversityFujian Cancer Hospital; Huizhou Municipal Central Hospital; Chipscreen Biosciences... et autres collaborateursRecrutementLeucémie, myéloïde, aiguë | Stade de la LAM, adulteChine
About CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited ("CSPC") (Stock code: 1093.HK) is a leading pharmaceutical group in China. The Company has been listed on the Main Board of the Hong Kong Stock Exchange since 1994 and became a constituent stock of the Hang Sang Index in 2018 (the 1st constituent stock in the pharmaceutical sector since launch of the index). CSPC is currently also a constituent stock of the "Hang Seng Composite Index", "Hang Seng Healthcare Index", "Hang Seng SCHK Mainland China Healthcare Index", "Hang Seng Stock Connect Hong Kong Index", "Hang Seng China (Hong Kong-listed) 100 Index" and "Hang Seng China Enterprises Index". CSPC mainly owns two business segments of finished drugs and bulk drugs, with innovative drugs as the core development strategy. CSPC currently has a strong product portfolio in the therapeutic areas of nervous system disease, oncology, anti-infective and cardiovascular disease. Of which "NBP", "Domeisu", "Jinyouli", "Keaili" and "Xuanning" are the most popular innovative drug products in China. Bulk drug products include vitamin C, antibiotics and caffeine series. The manufacturing facilities of CSPC are mainly located in Shijiazhuang City, Hebei Province, China. CSPC has a national top R&D team with R&D bases in Shijiazhuang, Shanghai, Beijing and the United States, focusing on the discovery, research and development of small molecule targeted drugs, nano-drugs, monoclonal antibody drugs, bispecific antibody drugs, antibody-drug conjugates and biological drugs in the immune field. According to the World Brand Lab (one of the leading independent consultancy of brand valuation in the world), the "CSPC" brand was ranked among the "Top 500 Most Valuable Brands in China" for more than ten consecutive years since 2004. With regards to corporate social responsibility activities, CSPC has taken an important role in supporting social welfare charities. For example, CSPC has participated in charity campaigns regarding SARS, the Indonesian tsunami, the Sichuan earthquake, the Yushu earthquake, children with critical illness, among other volunteer services. CSPC is fully committed to continuous contributions to the society with a pragmatic attitude and solid actions.